<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39359767</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>04</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2049-0801</ISSN><JournalIssue CitedMedium="Print"><Volume>86</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Annals of medicine and surgery (2012)</Title><ISOAbbreviation>Ann Med Surg (Lond)</ISOAbbreviation></Journal><ArticleTitle>Clinical outcomes following hospitalization for COVID-19 in patients with cardiac sarcoidosis in the United States: a propensity-matched analysis from national inpatient sample database from April 2020 to December 2021.</ArticleTitle><Pagination><StartPage>5696</StartPage><EndPage>5703</EndPage><MedlinePgn>5696-5703</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/MS9.0000000000002474</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">The highly arrhythmogenic nature of cardiac sarcoidosis (CS) leads to high morbidity and mortality, the rates of which may be higher in COVID-19 patients. This study aimed to evaluate the outcomes of CS patients admitted to hospitals with COVID-19.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">The study utilised the 2020-2021 National Inpatient Sample database, examining primary COVID-19 cases in adults aged older than or equal to 18 years. Those with CS were identified using ICD-10 code "D86.85" and compared with and without propensity matching (1:10) to those without CS for baseline characteristics and primary outcomes of acute kidney injury (AKI), use of mechanical ventilation, cardiac arrest and mortality.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">In total, 2 543 912 COVID-19 cases were identified. Before propensity matching, CS patients were more likely to be younger (58.0 vs. 64.0 years, <i>P</i>&lt;0.01), male (64.0% vs. 52.6%, <i>P</i>=0.011), of Black ethnicity (60.0% vs. 15.9%, <i>P</i>&lt;0.01), exhibit higher Charlson Comorbidity Index (CCI) scores (3.00 vs. 1.00, <i>P</i>&lt;0.01) and had a higher incidence of in-hospital cardiac arrest (aOR 2.649, 95% CI 1.366-5.134, <i>P</i>=0.004). After propensity matching (CS, <i>N</i>=95; non-CS, <i>N</i>=875), those with CS were at a statistically significant reduced risk of AKI (aOR 0.484, <i>P</i>=0.01); however, the outcomes of death, cardiac arrest, mechanical ventilation, length of stay (LOS) and healthcare costs did not reach significance.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">In a propensity-matched cohort admitted with COVID-19, CS patients had a reduced risk of AKI, but comparable LOS, rates of cardiac arrest, mechanical ventilator use, and mortality. Future research is warranted to develop evidence-based guidelines for managing COVID-19 in patients with CS.</AbstractText><CopyrightInformation>Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mactaggart</LastName><ForeName>Sebastian</ForeName><Initials>S</Initials><Identifier Source="ORCID">0009-0000-7039-4269</Identifier><AffiliationInfo><Affiliation>Northumbria Healthcare NHS Foundation Trust, Newcastle.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahmed</LastName><ForeName>Raheel</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Cardiac Sarcoidosis Services, Royal Brompton Hospital.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Heart and Lung Institute, Imperial College London.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Riaz</LastName><ForeName>Asma</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Dow University of Health Sciences, Karachi.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tabassum</LastName><ForeName>Shehroze</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>King Edward Medical University, Lahore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramphul</LastName><ForeName>Kamleshun</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Independent Researcher, Mauritius.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bilal</LastName><ForeName>Maham</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Dow University of Health Sciences, Karachi.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jamil</LastName><ForeName>Yumna</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Dow University of Health Sciences, Karachi.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dulay</LastName><ForeName>Mansimran Singh</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Cardiac Sarcoidosis Services, Royal Brompton Hospital.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Alexander</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Cardiac Sarcoidosis Services, Royal Brompton Hospital.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahmed</LastName><ForeName>Mushood</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Rawalpindi Medical University, Rawalpindi, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sawatari</LastName><ForeName>Hiroyuki</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Hiroshima University, Hiroshima, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pekyi-Boateng</LastName><ForeName>Prince K</ForeName><Initials>PK</Initials><Identifier Source="ORCID">0000-0002-7206-6207</Identifier><AffiliationInfo><Affiliation>Korle Bu Teaching Hospital, Accra, Ghana.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Azzu</LastName><ForeName>Alessia</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Cardiac Sarcoidosis Services, Royal Brompton Hospital.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wells</LastName><ForeName>Athol</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Cardiac Sarcoidosis Services, Royal Brompton Hospital.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kouranos</LastName><ForeName>Vasilis</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Cardiac Sarcoidosis Services, Royal Brompton Hospital.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chahal</LastName><ForeName>Anwar</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Barts Heart Centre, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Inherited Cardiovascular Diseases, Department of Cardiology, Wellspan Health, York, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sharma</LastName><ForeName>Rakesh</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Cardiac Sarcoidosis Services, Royal Brompton Hospital.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Heart and Lung Institute, Imperial College London.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>08</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Ann Med Surg (Lond)</MedlineTA><NlmUniqueID>101616869</NlmUniqueID><ISSNLinking>2049-0801</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">NIS</Keyword><Keyword MajorTopicYN="N">cardiac sarcoidosis</Keyword><Keyword MajorTopicYN="N">covid-19</Keyword><Keyword MajorTopicYN="N">propensity matching</Keyword><Keyword MajorTopicYN="N">sarcoidosis</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>3</Day><Hour>10</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>3</Day><Hour>10</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>3</Day><Hour>4</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>8</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39359767</ArticleId><ArticleId IdType="pmc">PMC11444656</ArticleId><ArticleId IdType="doi">10.1097/MS9.0000000000002474</ArticleId><ArticleId IdType="pii">AMSU-D-24-01093</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kouranos V, Sharma R. Cardiac sarcoidosis: state-of-the-art review. Heart 2021;107:1591–1599.</Citation><ArticleIdList><ArticleId IdType="pubmed">33674355</ArticleId></ArticleIdList></Reference><Reference><Citation>Arkema EV, Grunewald J, Kullberg S, et al. . Sarcoidosis incidence and prevalence: a nationwide register-based assessment in Sweden. Eur Respir J 2016;48:1690–1699.</Citation><ArticleIdList><ArticleId IdType="pubmed">27471207</ArticleId></ArticleIdList></Reference><Reference><Citation>Mactaggart S, Ahmed R. The role of ICDs in patients with sarcoidosis—a comprehensive review. Curr Probl Cardiol 2024;49:102483.</Citation><ArticleIdList><ArticleId IdType="pubmed">38401822</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed R, Dulay MS, Liu A, et al. . Comparing outcomes of an ‘early’ versus ‘late’ diagnosis of cardiac sarcoidosis following a baseline presentation of high-grade atrioventricular block. Curr Probl Cardiol 2024;49:102577.</Citation><ArticleIdList><ArticleId IdType="pubmed">38653441</ArticleId></ArticleIdList></Reference><Reference><Citation>Mactaggart S, Ahmed R. Comparison of prognosis in isolated versus systemic manifestations of cardiac sarcoidosis. Curr Probl Cardiol 2024;49:102671.</Citation><ArticleIdList><ArticleId IdType="pubmed">38782195</ArticleId></ArticleIdList></Reference><Reference><Citation>Choudhary P, Shafaati M, Abu Salah MAH, et al. . Zoonotic diseases in a changing climate scenario: Revisiting the interplay between environmental variables and infectious disease dynamics. Travel Med Infect Dis 2024;58:102694.</Citation><ArticleIdList><ArticleId IdType="pubmed">38336336</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan MS, Shahid I, Anker SD, et al. . Cardiovascular implications of COVID-19 versus influenza infection: a review. BMC Med 2020;18:403.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7746485</ArticleId><ArticleId IdType="pubmed">33334360</ArticleId></ArticleIdList></Reference><Reference><Citation>Aveyard P, Gao M, Lindson N, et al. . Association between pre-existing respiratory disease and its treatment, and severe COVID-19: a population cohort study. Lancet Respir Med 2021;9:909–923.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8016404</ArticleId><ArticleId IdType="pubmed">33812494</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J, Huang DQ, Zou B, et al. . Epidemiology of COVID-19: a systematic review and meta-analysis of clinical characteristics, risk factors, and outcomes. J Med Virol 2021;93:1449–1458.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7436673</ArticleId><ArticleId IdType="pubmed">32790106</ArticleId></ArticleIdList></Reference><Reference><Citation>Priyanka, Chopra H, Choudhary OP. mRNA vaccines as an armor to combat the infectious diseases. Travel Med Infect Dis 2023;52:102550.</Citation><ArticleIdList><ArticleId IdType="pubmed">36754340</ArticleId></ArticleIdList></Reference><Reference><Citation>Priyanka, Abusalah MAH, Chopra H, et al. . Nanovaccines: a game changing approach in the fight against infectious diseases. Biomed Pharmacother 2023;167:115597.</Citation><ArticleIdList><ArticleId IdType="pubmed">37783148</ArticleId></ArticleIdList></Reference><Reference><Citation>Priyanka, Choudhary OP, Singh I. Protective immunity against COVID-19: Unravelling the evidences for humoral vs. cellular components. Travel Med Infect Dis 2021;39:101911.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7654327</ArticleId><ArticleId IdType="pubmed">33186686</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed JQ, Maulud SQ, Dhawan M, et al. . MicroRNAs in the development of potential therapeutic targets against COVID-19: a narrative review. J Infect Public Health 2022;15:788–799.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9221922</ArticleId><ArticleId IdType="pubmed">35751930</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhawan M, Priyanka, Parmar M, et al. . Convalescent plasma therapy against the emerging SARS-CoV-2 variants: delineation of the potentialities and risks. Int J Surg 2022;97:106204.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8717699</ArticleId><ArticleId IdType="pubmed">34974199</ArticleId></ArticleIdList></Reference><Reference><Citation>Baughman RP, Lower EE, Buchanan M, et al. . Risk and outcome of COVID-19 infection in sarcoidosis patients: results of a self-reporting questionnaire. Sarcoidosis Vasc Diffuse Lung Dis 2020;37:e2020009.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7883514</ArticleId><ArticleId IdType="pubmed">33597796</ArticleId></ArticleIdList></Reference><Reference><Citation>Taduru SS, Goyal A, Dalia T, et al. . Inpatient characteristics, complications, and outcomes of patients with cardiac sarcoidosis: a study from the National Inpatient Sample. Indian Heart J 2022;74:148–150.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9039686</ArticleId><ArticleId IdType="pubmed">35104459</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed R, Sawatari H, Amanullah K, et al. . Characteristics and outcomes of hospitalised patients with heart failure and sarcoidosis: a propenisty-matched analysis of the nationwide readmissions database 2010-2019. Am J Med 2024;137:751–760.e8.</Citation><ArticleIdList><ArticleId IdType="pubmed">38588938</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed R, Shahbaz H, Ramphul K, et al. . Racial disparities among patients with cardiac sarcoidosis and arrhythmias in the United States: a propensity matched-analysis from the national inpatient sample database 2016-2020. Curr Probl Cardiol 2024;49:102450.</Citation><ArticleIdList><ArticleId IdType="pubmed">38355077</ArticleId></ArticleIdList></Reference><Reference><Citation>Sawatari H, Chahal AA, Ahmed R, et al. . Impact of cardiac implantable electronic devices on cost and length of stay in patients with surgical aortic valve replacement and transcutaneous aortic valve implantation. Am J Cardiol 2023;192:69–78.</Citation><ArticleIdList><ArticleId IdType="pubmed">36753975</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed R, Sawatari H, Deshpande S, et al. . Impact of atrial fibrillation on outcomes of aortic valve implantation. Am J Cardiol 2022;163:50–57.</Citation><ArticleIdList><ArticleId IdType="pubmed">34772477</ArticleId></ArticleIdList></Reference><Reference><Citation>HCUP . Elixhauser comorbidity software refined for ICD-10-CM 2024. https://hcup-us.ahrq.gov/toolssoftware/comorbidityicd10/comorbidity_icd10.jsp</Citation></Reference><Reference><Citation>Mathew G, Agha R, Albrecht J, et al. . STROCSS 2021: Strengthening the reporting of cohort, cross-sectional and case-control studies in surgery. Int J Surg 2021;96:106165.</Citation><ArticleIdList><ArticleId IdType="pubmed">34774726</ArticleId></ArticleIdList></Reference><Reference><Citation>Ejaz R, Ashraf MT, Qadeer S, et al. . Gender-based incidence, recovery period, and mortality rate of COVID-19 among the population of district Attock, Pakistan. Braz J Biol 2021;83:e249125.</Citation><ArticleIdList><ArticleId IdType="pubmed">34669800</ArticleId></ArticleIdList></Reference><Reference><Citation>Kharroubi SA, Diab-El-Harake M. Sex-differences in COVID-19 diagnosis, risk factors and disease comorbidities: a large US-based cohort study. Front Public Health 2022;10:1029190.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9714345</ArticleId><ArticleId IdType="pubmed">36466473</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed R, Okafor J, Khattar R, et al. . The role of infliximab in treating refractory cardiac sarcoidosis. Case series and systematic review of literature. Sarcoidosis Vasc Diffuse Lung Dis 2024;41:e2024013.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11275548</ArticleId><ArticleId IdType="pubmed">38940716</ArticleId></ArticleIdList></Reference><Reference><Citation>Goto K, Uehara M, Okamoto K, et al. . The therapeutic dilemma of immunosuppressive drugs for refractory cardiac sarcoidosis in COVID-19 infection. ESC Heart Fail 2021;8:5577–5582.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8653200</ArticleId><ArticleId IdType="pubmed">34697891</ArticleId></ArticleIdList></Reference><Reference><Citation>Sze S, Pan D, Nevill CR, et al. . Ethnicity and clinical outcomes in COVID-19: a systematic review and meta-analysis. EClinicalMedicine 2020;29:100630.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7658622</ArticleId><ArticleId IdType="pubmed">33200120</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed R, Sharma R, Chahal CAA. Trends and disparities around cardiovascular mortality in sarcoidosis: does big data have the answers? J Am Heart Assoc 2024;13:e034073.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11179766</ArticleId><ArticleId IdType="pubmed">38533935</ArticleId></ArticleIdList></Reference><Reference><Citation>Mues KE, Liede A, Liu J, et al. . Use of the Medicare database in epidemiologic and health services research: a valuable source of real-world evidence on the older and disabled populations in the US. Clin Epidemiol 2017;9:267–277.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5433516</ArticleId><ArticleId IdType="pubmed">28533698</ArticleId></ArticleIdList></Reference><Reference><Citation>Salazar A, Mañá J, Pintó X, et al. . Corticosteroid therapy increases HDL-cholesterol concentrations in patients with active sarcoidosis and hypoalphalipoproteinemia. Clin Chim Acta 2002;320:59–64.</Citation><ArticleIdList><ArticleId IdType="pubmed">11983201</ArticleId></ArticleIdList></Reference><Reference><Citation>Ivanišević J, Kotur-Stevuljević J, Stefanović A, et al. . Dyslipidemia and oxidative stress in sarcoidosis patients. Clin Biochem 2012;45:677–682.</Citation><ArticleIdList><ArticleId IdType="pubmed">22449334</ArticleId></ArticleIdList></Reference><Reference><Citation>Salazar A, Pintó X, Mañá J. Serum amyloid A and high-density lipoprotein cholesterol: serum markers of inflammation in sarcoidosis and other systemic disorders. Eur J Clin Invest 2001;31:1070–1077.</Citation><ArticleIdList><ArticleId IdType="pubmed">11903494</ArticleId></ArticleIdList></Reference><Reference><Citation>Feingold KR. Lipid and Lipoprotein Levels in Patients with COVID-19 Infections Feingold KR, Anawalt B, Blackman MR, et al.. Endotext. MDText.com, Inc. Copyright © 2000-2024, MDText.com, Inc.; 2000.</Citation><ArticleIdList><ArticleId IdType="pubmed">33237691</ArticleId></ArticleIdList></Reference><Reference><Citation>Desai R, Kakumani K, Fong HK, et al. . The burden of cardiac arrhythmias in sarcoidosis: a population-based inpatient analysis. Ann Transl Med 2018;6:330.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6174182</ArticleId><ArticleId IdType="pubmed">30306069</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahmoud AR, Dahy A, Dibas M, et al. . Association between sarcoidosis and cardiovascular comorbidity: a systematic review and meta-analysis. Heart Lung 2020;49:512–517.</Citation><ArticleIdList><ArticleId IdType="pubmed">32234258</ArticleId></ArticleIdList></Reference><Reference><Citation>Douglas JG, Middleton WG, Gaddie J, et al. . Sarcoidosis: a disorder commoner in non-smokers? Thorax 1986;41:787–791.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC460488</ArticleId><ArticleId IdType="pubmed">3787509</ArticleId></ArticleIdList></Reference><Reference><Citation>Harf RA, Ethevenaux C, Gleize J, et al. . Reduced prevalence of smokers in sarcoidosis. Results of a case-control study. Ann N Y Acad Sci 1986;465:625–631.</Citation><ArticleIdList><ArticleId IdType="pubmed">3460400</ArticleId></ArticleIdList></Reference><Reference><Citation>Bresnitz EA, Stolley PD, Israel HL, et al. . Possible risk factors for sarcoidosis. A case-control study. Ann N Y Acad Sci 1986;465:632–642.</Citation><ArticleIdList><ArticleId IdType="pubmed">3460401</ArticleId></ArticleIdList></Reference><Reference><Citation>Rybicki BA, Major M, Popovich J, Jr., et al. . Racial differences in sarcoidosis incidence: a 5-year study in a health maintenance organization. Am J Epidemiol 1997;145:234–241.</Citation><ArticleIdList><ArticleId IdType="pubmed">9012596</ArticleId></ArticleIdList></Reference><Reference><Citation>Tendolkar M, Tyagi R, Marwah V, et al. . Sarcoidosis and smoking: a systematic review and meta-analysis. J Marine Med Soc 2024;26:170–173.</Citation></Reference><Reference><Citation>Bergner R, Hoffmann M, Waldherr R, et al. . Frequency of kidney disease in chronic sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2003;20:126–132.</Citation><ArticleIdList><ArticleId IdType="pubmed">12870722</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed R, Najam N, Ramphul K, et al. . Characteristics and clinical outcomes of patients with sarcoidosis admitted for ST-elevation myocardial infarction in the United States: a propensity matched analysis from the National Inpatient Sample. Arch Med Sci Atheroscler Dis 2024;9:e47–e55.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11155460</ArticleId><ArticleId IdType="pubmed">38846054</ArticleId></ArticleIdList></Reference><Reference><Citation>Oliveros E, Patel H, Kyung S, et al. . Hypertension in older adults: assessment, management, and challenges. Clin Cardiol 2020;43:99–107.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7021657</ArticleId><ArticleId IdType="pubmed">31825114</ArticleId></ArticleIdList></Reference><Reference><Citation>Benmelouka AY, Abdelaal A, Mohamed ASE, et al. . Association between sarcoidosis and diabetes mellitus: a systematic review and meta-analysis. Expert Rev Respir Med 2021;15:1589–1595.</Citation><ArticleIdList><ArticleId IdType="pubmed">34018900</ArticleId></ArticleIdList></Reference><Reference><Citation>Cozier YC, Coogan PF, Govender P, et al. . Obesity and weight gain in relation to incidence of sarcoidosis in US black women: data from the Black Women’s Health Study. Chest 2015;147:1086–1093.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4388117</ArticleId><ArticleId IdType="pubmed">25411869</ArticleId></ArticleIdList></Reference><Reference><Citation>Procaccini C, Jirillo E, Matarese G. Leptin as an immunomodulator. Mol Aspects Med 2012;33:35–45.</Citation><ArticleIdList><ArticleId IdType="pubmed">22040697</ArticleId></ArticleIdList></Reference><Reference><Citation>Brito-Zerón P, Acar-Denizli N, Sisó-Almirall A, et al. . The burden of comorbidity and complexity in sarcoidosis: impact of associated chronic diseases. Lung 2018;196:239–248.</Citation><ArticleIdList><ArticleId IdType="pubmed">29230534</ArticleId></ArticleIdList></Reference><Reference><Citation>Martusewicz-Boros MM, Boros PW, Wiatr E, et al. . What comorbidities accompany sarcoidosis? A large cohort (n=1779) patients analysis. Sarcoidosis Vasc Diffuse Lung Dis 2015;32:115–120.</Citation><ArticleIdList><ArticleId IdType="pubmed">26278690</ArticleId></ArticleIdList></Reference><Reference><Citation>Pohle S, Baty F, Brutsche M. In-Hospital Disease Burden of Sarcoidosis in Switzerland from 2002 to 2012. PLoS One 2016;11:e0151940.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4795542</ArticleId><ArticleId IdType="pubmed">26987059</ArticleId></ArticleIdList></Reference><Reference><Citation>Nowiński A, Puścińska E, Goljan A, et al. . The influence of comorbidities on mortality in sarcoidosis: a observational prospective cohort study. Clin Respir J 2017;11:648–656.</Citation><ArticleIdList><ArticleId IdType="pubmed">26470754</ArticleId></ArticleIdList></Reference><Reference><Citation>Neville E, Walker AN, James DG. Prognostic factors predicting the outcome of sarcoidosis: an analysis of 818 patients. Q J Med 1983;52:525–533.</Citation><ArticleIdList><ArticleId IdType="pubmed">6657915</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajkumar T, Lea-Henry T, Chacko B. Acute kidney injury as the presenting manifestation of sarcoidosis: a case series and review of literature. Nephrology (Carlton) 2018;23:597–600.</Citation><ArticleIdList><ArticleId IdType="pubmed">28976049</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C, Liu H, Zhang T, et al. . Acute kidney injury as a rare manifestation of pediatric sarcoidosis: a case report and systematic literature review. Clin Chim Acta 2019;489:68–74.</Citation><ArticleIdList><ArticleId IdType="pubmed">30414436</ArticleId></ArticleIdList></Reference><Reference><Citation>Chávez-Valencia V, Orizaga-de-la-Cruz C, Lagunas-Rangel FA. Acute kidney injury in COVID-19 patients: pathogenesis, clinical characteristics, therapy, and mortality. Diseases 2022;10:53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9397016</ArticleId><ArticleId IdType="pubmed">35997358</ArticleId></ArticleIdList></Reference><Reference><Citation>Kouranos V, Khattar RS, Okafor J, et al. . Predictors of outcome in a contemporary cardiac sarcoidosis population: role of brain natriuretic peptide, left ventricular function and myocardial inflammation. Eur J Heart Fail 2023;25:2287–2298.</Citation><ArticleIdList><ArticleId IdType="pubmed">37877328</ArticleId></ArticleIdList></Reference><Reference><Citation>Okafor J, Khattar R, Kouranos V, et al. . Role of serial (18)F-fludeoxyglucose positron emission tomography in determining the therapeutic efficacy of immunosuppression and clinical outcome in patients with cardiac sarcoidosis. J Nucl Cardiol 2024;35:101842.</Citation><ArticleIdList><ArticleId IdType="pubmed">38479574</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhawan M, Priyanka, Choudhary OP. Immunomodulatory and therapeutic implications of vitamin D in the management of COVID-19. Hum Vaccin Immunother 2022;18:2025734.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8993102</ArticleId><ArticleId IdType="pubmed">35072581</ArticleId></ArticleIdList></Reference><Reference><Citation>Mactaggart S, Ahmed R. ICD in cardiac sarcoidosis: variables associated with appropriate therapy, inappropriate therapy, and device complications. Journal of Respiration 2024;4:102–111.</Citation></Reference><Reference><Citation>Ahmed R, Sivasankaran K, Ahsan A, et al. . Clinical outcomes with cardiac resynchronization therapy in patients with cardiac sarcoidosis: a systematic review and proportional meta-analysis. Curr Prob Cardiol 2024;49:102747.</Citation><ArticleIdList><ArticleId IdType="pubmed">39009251</ArticleId></ArticleIdList></Reference><Reference><Citation>Sultanian P, Lundgren P, Strömsöe A, et al. . Cardiac arrest in COVID-19: characteristics and outcomes of in- and out-of-hospital cardiac arrest. A report from the Swedish Registry for Cardiopulmonary Resuscitation. Eur Heart J 2021;42:1094–1106.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7928992</ArticleId><ArticleId IdType="pubmed">33543259</ArticleId></ArticleIdList></Reference><Reference><Citation>https://www.researchregistry.com/browse-the-registry#home/ Research Registry. Browse the Registry, Research Registrations 2024.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>